These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27018266)

  • 81. The Roles of Embryonic Transcription Factor BRACHYURY in Tumorigenesis and Progression.
    Chen M; Wu Y; Zhang H; Li S; Zhou J; Shen J
    Front Oncol; 2020; 10():961. PubMed ID: 32695672
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Brachyury and related Tbx proteins interact with the Mixl1 homeodomain protein and negatively regulate Mixl1 transcriptional activity.
    Pereira LA; Wong MS; Lim SM; Sides A; Stanley EG; Elefanty AG
    PLoS One; 2011; 6(12):e28394. PubMed ID: 22164283
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack.
    Hamilton DH; McCampbell KK; Palena C
    Front Oncol; 2018; 8():143. PubMed ID: 29774202
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Brachyury: Strategies for Drugging an Intractable Cancer Therapeutic Target.
    Robinson H; McFarlane RJ; Wakeman JA
    Trends Cancer; 2020 Apr; 6(4):271-273. PubMed ID: 32209441
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Machine learning based tissue analysis reveals Brachyury has a diagnosis value in breast cancer.
    Li K; Wang Q; Lu Y; Pan X; Liu L; Cheng S; Wu B; Song Z; Gao W
    Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33734319
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells.
    Palena C; Fernando RI; Litzinger MT; Hamilton DH; Huang B; Schlom J
    Exp Biol Med (Maywood); 2011 May; 236(5):537-45. PubMed ID: 21427233
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Development of a Small Molecule Downmodulator for the Transcription Factor Brachyury.
    Chase DH; Bebenek AM; Nie P; Jaime-Figueroa S; Butrin A; Castro DA; Hines J; Linhares BM; Crews CM
    Angew Chem Int Ed Engl; 2024 Apr; 63(14):e202316496. PubMed ID: 38348945
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Small-molecule targeting of brachyury transcription factor addiction in chordoma.
    Sharifnia T; Wawer MJ; Chen T; Huang QY; Weir BA; Sizemore A; Lawlor MA; Goodale A; Cowley GS; Vazquez F; Ott CJ; Francis JM; Sassi S; Cogswell P; Sheppard HE; Zhang T; Gray NS; Clarke PA; Blagg J; Workman P; Sommer J; Hornicek F; Root DE; Hahn WC; Bradner JE; Wong KK; Clemons PA; Lin CY; Kotz JD; Schreiber SL
    Nat Med; 2019 Feb; 25(2):292-300. PubMed ID: 30664779
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Prognostic significance of expression of epithelial-mesenchymal transition driver brachyury in breast cancer and its association with subtype and characteristics.
    Lee KH; Kim EY; Yun JS; Park YL; Do SI; Chae SW; Park CH
    Oncol Lett; 2018 Jan; 15(1):1037-1045. PubMed ID: 29399164
    [TBL] [Abstract][Full Text] [Related]  

  • 90. An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition.
    Palena C; Fernando RI; Hamilton DH
    Oncoimmunology; 2014 Jan; 3(1):e27220. PubMed ID: 24575384
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Breaking into the brachyury world: ΔNp63 joins in.
    Sinha S
    Cell Cycle; 2010 Jul; 9(13):2495-6. PubMed ID: 20647747
    [No Abstract]   [Full Text] [Related]  

  • 92. Metadherin regulates epithelial-mesenchymal transition in carcinoma.
    Wang Z; Tang ZY; Yin Z; Wei YB; Liu LF; Yan B; Zhou KQ; Nian YQ; Gao YL; Yang JR
    Onco Targets Ther; 2016; 9():2429-36. PubMed ID: 27143938
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Prostate cancer: Brachyury--a biomarker for progression and prognosis?
    Thoma C
    Nat Rev Urol; 2014 Sep; 11(9):485. PubMed ID: 25069730
    [No Abstract]   [Full Text] [Related]  

  • 94. Curcuminoids as Modulators of EMT in Invasive Cancers: A Review of Molecular Targets With the Contribution of Malignant Mesothelioma Studies.
    Pouliquen DL; Boissard A; Henry C; Coqueret O; Guette C
    Front Pharmacol; 2022; 13():934534. PubMed ID: 35873564
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The people behind the papers - Emily Bulgar and Benoit Bruneau.
    Development; 2024 Mar; 151(6):. PubMed ID: 38546044
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Brachyury: a new player in promoting breast cancer aggressiveness.
    Pires MM; Aaronson SA
    J Natl Cancer Inst; 2014 May; 106(5):. PubMed ID: 24815862
    [No Abstract]   [Full Text] [Related]  

  • 97. Neural networks as expert systems in rheumatic disease diagnosis: artificial intelligence or intelligent artifice?
    Astion ML; Bloch DA; Wener MH
    J Rheumatol; 1993 Sep; 20(9):1465-8. PubMed ID: 8164199
    [No Abstract]   [Full Text] [Related]  

  • 98. Comparison of Methodologies Using Estimated or Measured Values of Total Corneal Astigmatism for Toric Intraocular Lens Power Calculation.
    Ferreira TB; Ribeiro P; Ribeiro FJ; O'Neill JG
    J Refract Surg; 2017 Dec; 33(12):794-800. PubMed ID: 29227506
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Early mobilization versus bed rest for deep vein thrombosis.
    Izcovich A; Popoff F; Rada G
    Medwave; 2016 Jun; 16 Suppl 2():e6478. PubMed ID: 27391009
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Three-dimensional solubility parameters and their use in characterising the permeation of drugs through the skin.
    Groning R; Braun FJ
    Pharmazie; 1996 May; 51(5):337-41. PubMed ID: 8710956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.